XBiotech Inc (XBIT) was Reiterated by Noble Financial to “Buy” according to the research note released today. The brokerage firm has raised the Price Target to $ 30 from a previous price target of $24 . Noble Financial advised their investors in a research report released on Jun 28, 2016.
XBiotech Inc opened for trading at $18.1 and hit $18.85 on the upside on Monday, eventually ending the session at $18.84, with a gain of 3.74% or 0.68 points. The heightened volatility saw the trading volume jump to 3,44,665 shares. Company has a market cap of $609 M.
In a different news, on Dec 23, 2015, Queena Han (VP Finance / HR) sold 30,000 shares at $10.51 per share price. According to the SEC, on Nov 19, 2015, Michael Stecher (Medical Director) sold 1,800 shares at $14.00 per share price.
XBiotech Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in discovering and developing True Humanmonoclonal antibodies for treating various diseases. The Company focuses to develop MABp1 a therapeutic antibody which specifically neutralizes interleukin-1 alpha (IL-1a). IL-1a is a pro-inflammatory protein produced by leukocytes and other cells where it plays arole in inflammation. The Company has completed a Phase I/II clinical trials for MABp1 (Xilonix) as a treatment for cancer at MD Anderson Cancer Center. The Company is also involved in investigating MABp1 in clinical trials for other indicationsincluding vascular disease type II diabetes acne and psoriasis. The Company has begun using its True Human antibody technology for developing a therapy for Ebola virus infection.